In the phase 3 trials of both the JAK1/JAK2 inhibitor ruxolitinib and JAK2/FLT3 inhibitor fedratinib, indicators of anemia worsening such as decreased mean hemoglobin levels and increased transfusions were evident in the initial weeks of treatment [46,47,48]. Here, JAK1 is linked to anemia.